Photodynamic Therapy of Bladder Cancer - A Phase I Study Using Hexaminolevulinate (HAL)

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1178-1183

  Bader, M J ^a   Stepp, Herbert ^a   Beyer, Wolfgang ^a   Pongratz, Thomas ^a   Sroka, Ronald ^a   Kriegmair, Martin ^b   Zaak, Dirk ^c   Welschof, Mona ^d   Tilki, Derya ^a   Stief, Christian G ^a   Waidelich, Raphaela ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Urological Clinic Dr Castringius Munich Planegg   (Germany)

^c Urology Clinic Traunstein   (Germany)

^d PhotoCure ASA   (Norway)

Author keywords

Bladder cancer; Hexaminolevulinate; Photodynamic therapy; Protoporphyrin fluorescence

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRITATION; BLADDER SURGERY; CLINICAL ARTICLE; CYSTOSCOPY; CYTOPATHOLOGY; DRUG SAFETY; FEMALE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROHEMATURIA; MALE; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION OF THE BLADDER; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

BLADDER CANCER; HEXAMINOLEVULINATE; PHOTODYNAMIC THERAPY; PROTOPORPHYRIN FLUORESCENCE;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CYSTOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; URINARY TRACT INFECTIONS; UROLOGIC DISEASES;

EID: 84884676208     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.02.007     Document Type: Article

References (23)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49. 466-5, Discussion:75-7.
2. Waidelich R., Stepp H., Baumgartner R., et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001, 165:1904-1907.
3. Nseyo U.O., Shumaker B., Klein E.A., et al. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 1998, 160:39-44. Bladder Photofrin Study Group.
4. Jocham D., Stepp H., Waidelich R. Photodynamic diagnosis in urology: State-of-the-art. Eur Urol 2008, 53:1138-1148.
5. Kriegmair M., Baumgartner R., Lumper W., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996, 77:667-671.
6. Waidelich R., Hofstetter A., Stepp H., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol 1998, 159:401-404.
7. Berger A.P., Steiner H., Stenzl A., et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: A single-center study. Urology 2003, 61:338-341.
8. Waidelich R., Beyer W., Knüchel R., et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003, 61:332-337.
9. Lange N., Jichlinski P., Zellweger M., et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexyl ester-induced protoporphyrin IX: A pilot study. Br J Cancer 1999, 80:185-193.
10. Marti A., Jichlinski P., Lange N., et al. Comparison of aminolevulinic acid and hexyl ester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003, 170:428-432.
11. Gronlund-Pakkanen S., Wahlfors J., Makinen K., et al. The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma. J Urol 2002, 167:1848-1853.
12. Xiao Z., Miller G.G., McCallum T.J., et al. Biodistribution of photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: Implications for photodynamic therapy. Photochem Photobiol 1998, 67:573-583.
13. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: New diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003, 170:226-229.
14. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005, 174:862-866. Discussion:66.
15. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study. J Urol 2007, 178:68-73. Discussion:73.
16. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007, 178:62-67.
17. Schmidbauer J., Witjes F., Schmeller N., et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171:135-138.
18. Stenzl A., Burger M., Fradet Y., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non-muscle-invasive bladder cancer. J Urol 2010, 184:1907-1913.
19. Shackley D.C., Briggs C., Gilhooley A., et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int 2002, 89:665-670.
20. Ma L., Bagdonas S., Moan J. The photosensitizing effect of the photoproduct of protoporphyrin IX. J Photochem Photobiol B Biol 2001, 60:108-113.
21. Mowatt G., Zhu S., Kilonzo M., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14:1-331. iii-iv.
22. Draga R.O., Grimbergen M.C., Kok E.T., et al. Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: Identification of patient groups that may benefit most from highly specific optical diagnostics. Urology 2009, 74:851-856.
23. Draga R.O., Grimbergen M.C., Kok E.T., et al. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. Eur Urol 2010, 57:655-660.